iAnthus Capital (ITHUF) Stock Price, News & Analysis

Company Overview

iAnthus Capital (OTCMKTS: ITHUF) is a multi-state operator in the U.S. medical cannabis industry. The company acquires, develops and manages licensed cultivation, processing and retail facilities in regulated state markets. Its core business activities include the cultivation of cannabis flower, the manufacturing of extracts and infused products such as oils, edibles and topicals, and the operation of dispensaries under various regional brands.

Through a network of subsidiaries and strategic acquisitions, iAnthus holds medical cannabis licenses in multiple states, including Florida, New York, Massachusetts and Maryland. The company’s cultivation sites follow Good Manufacturing Practices (GMP) standards, and its vertically integrated model allows for tight control over quality, traceability and compliance from seed to sale. Retail operations are branded to reflect local market preferences, featuring educational programs for patients and caregivers.

Founded in 2014, iAnthus Capital originally listed on the Canadian Securities Exchange before expanding its footprint across the United States. Growth has been driven by targeted acquisitions, including the 2020 business combination with MPX Bioceutical, which broadened the company’s presence in southeastern markets. iAnthus has positioned itself as a partner of choice for state regulators, emphasizing a patient-centric approach and adherence to evolving legal frameworks.

Headquartered in New York, iAnthus is led by CEO Hadley Ford, whose background spans regulated-market operator development and public company management. The senior leadership team focuses on operational excellence, state licensing strategy and the development of differentiated product portfolios. With a blend of cultivation expertise and retail experience, the company seeks to capture emerging opportunities as new markets open to medical and adult-use cannabis.

Key Stats

• Today's Range: $0.0044 to $0.0046
• 50-Day Range: N/A
• 52-Week Range: $0.0031 to $0.0133
• Volume: 225,436 shs
• Average Volume: 309,043 shs
• Market Capitalization: N/A
• P/E Ratio: 0.03
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

iAnthus Capital Stock Analysis - MarketRank™

iAnthus Capital scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for iAnthus Capital.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of iAnthus Capital is 0.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.17.

Price to Earnings Ratio vs. Sector

The P/E ratio of iAnthus Capital is 0.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.78.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

iAnthus Capital has a short interest ratio ("days to cover") of 0.03, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iAnthus Capital has recently decreased by 43.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iAnthus Capital does not currently pay a dividend.

Dividend Growth

iAnthus Capital does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.81

News Sentiment

iAnthus Capital has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for iAnthus Capital this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iAnthus Capital insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.34% of the stock of iAnthus Capital is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Agriculture
• Current Symbol: OTCMKTS:ITHUF
• CIK: 1643154
• Web: www.ianthuscapital.com
• Phone: 646-518-9411
• Fax: N/A
• Employees: 1,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.03
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A